Evidence map›Paper›PMID 36313633›Full record

ArticleFrontiers in oncology2022

Temporal radiographic and histological study of necrosis development in a mouse glioblastoma model.

Patricia P Yee, Jianli Wang, Stephen Y Chih, Dawit G Aregawi, Michael J Glantz, Brad E Zacharia, Krishnamoorthy Thamburaj, Wei Li

Abstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Patricia P YeeDivision of Hematology and Oncology, Department of Pediatrics, Penn State College of Medicine, Hershey, PA, United States.
Jianli WangDepartment of Radiology, Penn State College of Medicine, Hershey, PA, United States.
Stephen Y ChihDivision of Hematology and Oncology, Department of Pediatrics, Penn State College of Medicine, Hershey, PA, United States.
Dawit G AregawiNeuro-Oncology Program, Department of Neurosurgery, Penn State College of Medicine, Hershey, PA, United States.
Michael J GlantzNeuro-Oncology Program, Department of Neurosurgery, Penn State College of Medicine, Hershey, PA, United States.
Brad E ZachariaNeuro-Oncology Program, Department of Neurosurgery, Penn State College of Medicine, Hershey, PA, United States.
Krishnamoorthy ThamburajDepartment of Radiology, Penn State College of Medicine, Hershey, PA, United States.
Wei LiDivision of Hematology and Oncology, Department of Pediatrics, Penn State College of Medicine, Hershey, PA, United States.

Funding

The role and mechanism of necrosis in glioblastomaR01NS119547 · NINDS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI LI, WEI · 2021 to 2025
$1.9M
The role of NONO in TAZ-driven glioma malignant transformationR01NS109147 · NINDS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI LI, WEI · 2018 to 2022
$1.7M
NINDS NIH HHS R01 NS109147NINDS NIH HHS R01 NS119547
6 · The paper itself

Abstract

Tumor necrosis is a poor prognostic marker in glioblastoma (GBM) and a variety of other solid cancers. Accumulating evidence supports that necrosis could facilitate tumor progression and resistance to therapeutics. GBM necrosis is typically first detected by magnetic resonance imaging (MRI), after prominent necrosis has already formed. Therefore, radiological appearances of early necrosis formation and the temporal-spatial development of necrosis alongside tumor progression remain poorly understood. This knowledge gap leads to a lack of reliable radiographic diagnostic/prognostic markers in early GBM progression to detect necrosis. Recently, we reported an orthotopic xenograft GBM murine model driven by hyperactivation of the Hippo pathway transcriptional coactivator with PDZ-binding motif (TAZ) which recapitulates the extent of GBM necrosis seen among patients. In this study, we utilized this model to perform a temporal radiographic and histological study of necrosis development. We observed tumor tissue actively undergoing necrosis first appears more brightly enhancing in the early stages of progression in comparison to the rest of the tumor tissue. Later stages of tumor progression lead to loss of enhancement and unenhancing signals in the necrotic central portion of tumors on T1-weighted post-contrast MRI. This central unenhancing portion coincides with the radiographic and clinical definition of necrosis among GBM patients. Moreover, as necrosis evolves, two relatively more contrast-enhancing rims are observed in relationship to the solid enhancing tumor surrounding the central necrosis in the later stages. The outer more prominently enhancing rim at the tumor border probably represents the infiltrating tumor edge, and the inner enhancing rim at the peri-necrotic region may represent locally infiltrating immune cells. The associated inflammation at the peri-necrotic region was further confirmed by immunohistochemical study of the temporal development of tumor necrosis. Neutrophils appear to be the predominant immune cell population in this region as necrosis evolves. This study shows central, brightly enhancing areas associated with inflammation in the tumor microenvironment may represent an early indication of necrosis development in GBM.

Indexed as

Glioblastomamagnetic resonance imagingmouse modelMRITAZtumor necrosis

Identifiers

PMID36313633
PMCPMC9614031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.